Trials / Recruiting
RecruitingNCT06999434
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Conditions
- Demyelinating Disorders
- MCI
- Alzheimer's Disease (AD)
- MS (Multiple Sclerosis)
- SCI - Spinal Cord Injury
- Spinal Radiculopathy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [ 18F]3F4AP | PET Scan #3 |
| DRUG | [18F]MK6240 | PET Scan #2 |
| DRUG | [11C]PIB | PET Scan #1 |
Timeline
- Start date
- 2025-05-05
- Primary completion
- 2030-05-05
- Completion
- 2030-05-05
- First posted
- 2025-05-31
- Last updated
- 2025-05-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06999434. Inclusion in this directory is not an endorsement.